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The activation of Group 1 metabotropic glutamate re-
ceptors, mGluR5 and mGluR1, triggers intracellular
calcium release; however, mGluR5 activation is unique
in that it elicits Ca2 oscillations. A short region of the
mGluR5 C terminus is the critical determinant and dif-
fers from the analogous region of mGluR1 by a single
amino acid residue, Thr-840, which is an aspartic acid
(Asp-854) in mGluR1. Previous studies show that
mGluR5-elicited Ca2 oscillations require protein ki-
nase C (PKC)-dependent phosphorylation and identify
Thr-840 as the phosphorylation site. However, direct
phosphorylation of mGluR5 has not been studied in de-
tail. We have used biochemical analyses to directly in-
vestigate the phosphorylation of the mGluR5 C termi-
nus. We showed that Ser-839 on mGluR5 is directly
phosphorylated by PKC, whereas Thr-840 plays a per-
missive role. Although Ser-839 is conserved in mGluR1
(Ser-853), it is not phosphorylated, as the adjacent resi-
due (Asp-854) is not permissive; however, mutagenesis
of Asp-854 to a permissive alanine residue allows phos-
phorylation of Ser-853 on mGluR1. We investigated the
physiological consequences of mGluR5 Ser-839 phos-
phorylation using Ca2 imaging. Mutations that elimi-
nate Ser-839 phosphorylation prevent the characteristic
mGluR5-dependent Ca2 oscillations. However, muta-
tion of Thr-840 to alanine, which prevents potential Thr-
840 phosphorylation but is still permissive for Ser-839
phosphorylation, has no effect on Ca2 oscillations.
Thus, we showed that it is phosphorylation of Ser-839,
not Thr-840, that is absolutely required for the unique
Ca2 oscillations produced by mGluR5 activation. The
Thr-840 residue is important only in that it is permissive
for the PKC-dependent phosphorylation of Ser-839.
Metabotropic glutamate receptors (mGluRs)1 play important
roles throughout the nervous system, including the activation
of ion channels and the regulation of synaptic plasticity (1). In
addition, they have been implicated in a variety of neurological
diseases (2–5). There are eight different mGluRs, and these are
subdivided into three groups based on sequence identity and
pharmacological properties. Group 1 mGluRs (mGluR1 and
mGluR5) are linked to phospholipase C, whereas Group 2
mGluRs (mGluR2 and mGluR3) and Group 3 mGluRs
(mGluR4, mGluR6, mGluR7, and mGluR8) are negatively
linked to adenylate cyclase. Activation of Group 1 mGluRs
triggers phospholipase C, resulting in increases in IP3 and
diacylglycerol production and the concomitant release of intra-
cellular Ca2 and activation of protein kinase C (PKC) (6).
Group 1 mGluR-elicited Ca2 release stimulates PKC translo-
cation to the plasma membrane and oscillations of both PKC
activation and IP3 production (7, 8).
Although both mGluR1 and mGluR5 stimulate intracellular
Ca2 release, they differ in that mGluR5 activation results in
Ca2 oscillations, whereas mGluR1 activation results in a sin-
gle Ca2 transient with or without subsequent low frequency
oscillations (9, 10). A previous study (10) demonstrated that a
short stretch of amino acids in the C terminus of mGluR5 was
the critical determinant regulating Ca2 oscillations, specifi-
cally the identity of a single amino acid residue, Thr-840. In
addition, it was reported that the direct phosphorylation of
Thr-840 by PKC was the mechanism regulating the Ca2 os-
cillations (10). In the current study, we have investigated the
direct phosphorylation of mGluR5 by PKC using phosphopep-
tide analysis. Surprisingly, we demonstrated that Thr-840 is
not a PKC substrate but only plays a permissive role for PKC
phosphorylation of the adjacent amino acid Ser-839. Conse-
quently, it is the PKC phosphorylation of Ser-839 that regu-
lates mGluR5-elicited Ca2 oscillations. Furthermore, we
showed that the analogous serine in mGluR1, Ser-853, is not
phosphorylated due to an adjacent aspartic acid residue but
can be phosphorylated when the adjacent amino acid is mu-
tated to a permissive residue. Therefore, we have found that
Thr-840 of mGluR5 and Asp-854 of mGluR1 are the critical
determinants of the distinct Ca2 transients elicited by
mGluR5 and mGluR1, respectively. However, our data clearly
demonstrate that this is because of the differential effect these
residues have on the PKC phosphorylation of a conserved ad-
jacent serine, not because of the direct PKC phosphorylation of
Thr-840 on mGluR5.
EXPERIMENTAL PROCEDURES
DNA Constructs and Site-directed Mutagenesis—The mGluR5 cDNA
was a generous gift from Dr. S. Nakanishi (Kyoto University). The
full-length C terminus (amino acids 828–1171) and first one-third of the
C terminus (amino acids 828–944) of mGluR5 were amplified from rat
mGluR5 cDNA using PCR. The first one-third of the C terminus (amino
acids 842–958) of rat mGluR1 was also amplified by PCR. The PCR
products were then digested with EcoRI and subcloned in-frame into
pGEX-4T-1 GST fusion vector (Amersham Biosciences). mGluR5
(S839A, T840A, T840D, S834A, T837A, and T838A) and mGluR1
(S853A, D854A, D854T, and S853A/D854A) mutations on GST fusion
constructs or pRK5-mGluR5 were generated using the QuikChange
site-directed mutagenesis system (Stratagene, La Jolla, CA) following
the manufacturer’s instructions. Mutations were confirmed by se-
quence analysis.
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Fusion Protein Production and in Vitro Phosphorylation—Fusion
proteins for wild-type and mutant C termini of mGluR5 or mGluR1
were purified for the most part in accordance with the protocol provided
by the manufacturer (Amersham Biosciences). In brief, DNA constructs
were transformed into BL21 bacterial cells. 50-ml cultures were grown
until the cultures reached the mid-log phase of growth (A550  0.5–1.0)
after adding 1 ml of overnight cultures. Isopropyl 1-thio--D-galactopy-
ranoside (1 mM) was added to cultures to induce fusion protein expres-
sion. After 4 h of induction, the cells were lysed with 5 ml of B-PER
bacterial protein extraction reagent (Pierce, Rockford, IL). The bacterial
lysates were incubated with glutathione-Sepharose 4B (Amersham Bio-
sciences) for 30 min, and then the beads were washed with 10 bed
volume of phosphate-buffered saline. The fusion proteins were eluted
with 50 mM Tris-HCl (pH 8.0) containing 10 mM reduced glutathione.
The fusion proteins were phosphorylated in 20 mM HEPES, pH 7.4, 1.67
mM CaCl2, 1 mM dithiothreitol, 10 mM MgCl2, 200 mM cold ATP, 1 pmol
of [-32P]ATP (3000 Ci/mmol) with 25 ng of purified PKC (Promega,
Madison, WI) at 30 °C for 30 min. The reactions were stopped by adding
SDS-PAGE sample buffer, and the samples were boiled for 5 min. The
phosphorylated proteins were resolved by SDS-PAGE and transferred
to nitrocellulose membrane (Schleicher & Schuell, Keene, NH). The
bands were visualized by autoradiography and were excised for in vitro
phosphopeptide mapping.
Two-dimensional Phosphopeptide Mapping—Peptide mapping was
performed as previously described (11, 12). Briefly, phosphorylated
proteins were resolved by SDS-PAGE and transferred to nitrocellulose.
The relevant bands were excised and soaked for 1 h in tubes containing
1 ml of 1% polyvinylpyrrolidone-40 in 100 mM acetic acid. After washing
with 0.4% NH4HCO3, the proteins on the membrane were digested with
trypsin overnight at 37 °C. Supernatants containing the tryptic diges-
tion products were dried in a SpeedVac, washed twice with 900 l of
H2O, and resuspended in 5 l of H2O. One or two l of the dissolved
phosphopeptides were spotted onto a cellulose thin layer chromatogra-
phy plate (Merck). The phosphopeptides were resolved in the first
dimension by electrophoresis in buffer containing 2.5% formic acid and
7.8% acetic acid. Separation by ascending chromatography in the sec-
ond dimension was performed using buffer containing 62.5% isobutyric
acid, 4.8% pyridine, 1.9% butanol, and 2.9% acetic acid. The thin layer
chromatography plate was air-dried, and the peptide map was visual-
ized by PhosphorImager analysis.
Measurement of Ca2 Oscillations—HeLa cells (American Type Cul-
ture Collection CCL-2) were grown in Dulbecco’s modified Eagle’s me-
dium containing 10% fetal bovine serum on coverglasses. The cells were
transfected with wild-type or mutant constructs of mGluR5 using Cal-
Phos mammalian calcium phosphate transfection kit (BD Biosciences).
The cells were incubated with transfectants 12 h before changing to
fresh medium and analyzed 36–48 h following transfection. The cells
were loaded with 5 M Oregon Green 488 BAPTA-1 AM (Molecular
Probes, Eugene, OR) for 30 min at 37 °C and then washed three times
with HEPES-buffered solution containing 135 mM NaCl, 5.4 mM KCl,
0.9 mMMgCl2, 1.8 mM CaCl2, and 10 mMHEPES. After 1 h of incubation
in the same buffer, confocal microscopy was performed on a Zeiss
LSM-510 laser-scanning microscope after the treatment of a mGluR5
agonist (500 M glutamate). A time scan was performed for 300 s for
each sample. Cells exhibiting a Ca2 response to agonist application
were classified as oscillating or non-oscillating, with oscillating cells
defined as those having oscillation frequencies 1/min with constant
amplitude and frequency and non-oscillating cells defined as those
having any calcium transients other than oscillations defined above,
including a single calcium peak, a single sustained calcium plateau, a
single calcium peak or a plateau with slow oscillations in a later phase,
or a single peak with a shoulder (8–10).
Generation of Phosphorylation State-specific Antibodies and Immu-
noblotting—Rabbit phosphospecific antibodies against phosphorylated
Ser-839 of mGluR5 were generated by BIOSOURCE International (Ca-
marillo, CA). Rabbits were immunized with a synthetic peptide N-
C(EE)FTT[pS]TVVR-C. The sera were collected and affinity-purified
using the antigen peptide. Amino acids in parentheses represent addi-
tional glutamic acid residues that were added to the N terminus of
peptides to promote solubility. Fusion proteins (wild-type GST-
mGluR5-Cprox, GST-mGluR5-Cprox (S839A), and GST alone) were
phosphorylated by purified PKC in vitro as described under “Fusion
Protein Production and in Vitro Phosphorylation.” Proteins were re-
solved by SDS-PAGE and transferred to a polyvinylidene difluoride
membrane. Phosphorylation of Ser-839 on mGluR5 C-terminal fusion
proteins was analyzed by immunoblotting with the pSer839 phos-
phospecific antibody.
RESULTS
PKC is an important modulator of mGluR function (10, 13–
17); however, the biochemical analyses characterizing the di-
rect phosphorylation of mGluRs by PKC have been lacking.
Therefore, we began to characterize the mGluR5 C terminus as
the region most likely to contain PKC phosphorylation sites. To
evaluate precisely the direct phosphorylation of the mGluR5 C
terminus by PKC, we generated a GST fusion protein contain-
ing the entire mGluR5 C terminus (GST-mGluR5-C; Fig. 1A).
Previous studies have reported the phosphorylation of specific
residues, including Thr-840, on mGluR5 within the proximal C
terminus near the seventh transmembrane domain (10, 18);
therefore, we also generated a GST fusion protein containing
the first one-third of the mGluR5 C terminus, GST-mGluR5-
Cprox (Fig. 1A). We performed an in vitro phosphorylation
assay to evaluate the direct phosphorylation of mGluR5 by
PKC. GST-mGluR5 fusion proteins were incubated with
[-32P]ATP and PKC for 30 min at 30 °C as described under
“Experimental Procedures.” The fusion proteins were then re-
solved by SDS-PAGE, the phosphorylated proteins were pro-
teolyzed with trypsin, and the peptide fragments were resolved
in two dimensions, resulting in a distinct phosphopeptide map.
The peptide map of the mGluR5 C terminus revealed multiple
phosphopeptides that varied in their intensity (Fig. 1B). Inter-
FIG. 1. The proximal one-third of the mGluR5 C terminus is
phosphorylated by PKC on sites other than T840. A, diagram of
C-terminal GST fusion proteins of the mGluR5 C terminus. B, the first
one-third of the mGluR5 C terminus contains the majority of the sites
phosphorylated by PKC. GST-mGluR5-C (amino acids 828–1171) and
GST-mGluR5-Cprox (amino acids 828–944) were phosphorylated by
purified PKC in vitro using [-32P]ATP and then subjected to two-
dimensional phosphopeptide mapping as described under “Experimen-
tal Procedures.” C, threonine 840 is not directly phosphorylated by
PKC. Wild-type GST-mGluR5-Cprox, GST-mGluR5-Cprox (T840A),
and mGluR5-Cprox (T840D) were phosphorylated by PKC in vitro using
[-32P]ATP and then subjected to two-dimensional phosphopeptide
mapping as described under “Experimental Procedures.” The phos-
phopeptide that includes Thr-840 is indicated with a white arrow. The
figures include representative phosphopeptide maps selected from 3–4
independent experiments.
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estingly, the peptide maps of GST-mGluR5-C and GST-
mGluR5-Cprox were indistinguishable (Fig. 1B). This was com-
pelling evidence that the major PKC phosphorylation sites on
the mGluR5 C terminus were contained within the proximal
one-third of this region. Therefore we used the GST-mGluR5-
Cprox fusion protein for further analysis.
We next wanted to evaluate the phosphorylation of Thr-840
within mGluR5, which had been reported to be the PKC sub-
strate responsible for regulating the Ca2 oscillations (10). We
began by evaluating PKC phosphorylation of the wild-type
mGluR5 C terminus and comparing it to the mGluR5 C termi-
nus containing an alanine mutation of the critical threonine
(GST-mGluR5-Cprox T840A). We performed in vitro phospho-
rylation of the wild-type GST-mGluR5-Cprox along with the
GST-mGluR5-Cprox (T840A). However, we found no change in
the peptide maps (Fig. 1C), which was surprising, as Thr-840
had been reported to be a PKC substrate (10). We also inves-
tigated the threonine to aspartic acid mutation (GST-mGluR5-
Cprox T840D) described in that study (10). In contrast to
T840A, we found that T840D did result in the disappearance of
a distinct phosphopeptide on the map compared with wild-type
mGluR5 (Fig. 1C). These data are therefore inconsistent with
the direct phosphorylation of Thr-840 by PKC, as both the
alanine and aspartic acid mutation would abolish direct phos-
phorylation of Thr-840. Instead, these experiments suggest
that the T840D mutant specifically disrupted the phosphoryl-
ation of some other site on mGluR5.
We therefore tested the alternative hypothesis that the iden-
tity of the 840 amino acid affects the substrate specificity of
PKC for a nearby residue. The first one-third of the mGluR5
C terminus contains many potential PKC phosphorylation
sites, with several serines and threonines included within
the predicted tryptic peptide fragment containing Thr-840
(834SAFTTSTVVR843). One candidate residue for PKC phos-
phorylation was the adjacent Ser-839 (Fig. 2A). To test this
hypothesis, we mutated Ser-839 to alanine (GST-mGluR5-
Cprox S839A) and evaluated it using the in vitro phosphoryl-
ation assay. We found that PKC phosphorylation of GST-
mGluR5-Cprox (S839A) resulted in a phosphopeptide map with
a phosphopeptide missing (Fig. 2B), yielding a map with the
same pattern as the peptide map of the T840D mutant (Fig.
1C). This was consistent with the T840D mutation disrupting
the PKC phosphorylation of the adjacent Ser-839. Further-
more, point mutations of the other serine and threonines
within the predicted peptide fragment (S834A, T837A, T838A)
did not affect phosphorylation and resulted in peptide maps
that did not differ from wild type (Fig. 2C). In addition to the
peptide map analysis, we also generated a phosphorylation
state-specific antibody recognizing mGluR5 phosphorylated on
Ser-839 to probe whether or not Ser-839 is directly phospho-
rylated. We performed an in vitro PKC phosphorylation assay
of GST, wild-type GST-mGluR5-Cprox, and GST-mGluR5-
Cprox (S839A), resolved the proteins by SDS-PAGE, and im-
munoblotted with our Ser-839 phosphoantibody. We found that
the antibody specifically recognized PKC-phosphorylated wild-
type GST-mGluR5-Cprox and did not recognize PKC-phospho-
rylated GST-mGluR5-Cprox (S839A), consistent with the direct
phosphorylation of Ser-839 in vitro (Fig. 2D).
Based on our mutagenesis studies of mGluR5, it followed
that mGluR1 might be phosphorylated by PKC on serine 853,
which is analogous to Ser-839 of mGluR5 (see alignment in Fig.
2A), when we replace the adjacent aspartic acid (Asp-854 in
wild-type mGluR1) with a permissive amino acid. To charac-
terize the direct phosphorylation of mGluR1, we made a GST
fusion protein of the proximal one-third of the mGluR1 C
terminus (GST-mGluR1-Cprox). We performed an in vitro
phosphorylation assay comparing the PKC phosphorylation of
wild-type GST-mGluR1-Cprox and GST-mGluR1-Cprox mu-
tants. Interestingly, the phosphopeptide map for mGluR1-
FIG. 2. Identification of Ser-839 as a PKC phosphorylation site
on mGluR5. A, alignment of mGluR1 (amino acids 841–861) and
mGluR5 (amino acids 827–847). B, serine 839 on mGluR5 was directly
phosphorylated by PKC. Wild-type (WT) GST-mGluR5-Cprox and GST-
mGluR5-Cprox (S839A) were phosphorylated by purified PKC in vitro
using [-32P]ATP and then subjected to two-dimensional phosphopep-
tide mapping, as described under “Experimental Procedures.” The
phosphopeptide that contains Ser-839 and Thr-840 is indicated with a
white arrow. C, other serine and threonine residues in the same region
of the mGluR5 C terminus were not phosphorylated by PKC. GST-
mGluR5-Cprox (S834A), GST-mGluR5-Cprox (T837A), and mGluR5-
Cprox (T838A) were phosphorylated by purified PKC in vitro using
[-32P]ATP and then subjected to two-dimensional phosphopeptide
mapping, as described under “Experimental Procedures.” D, serine 839
was phosphorylated in vitro as detected by a phosphorylation state-
specific antibody. Wild-type GST-mGluR5-Cprox, GST-mGluR5-Cprox
(S839A), and GST alone were phosphorylated by purified PKC in vitro.
The proteins were resolved by SDS-PAGE, transferred to a polyvinyli-
dene difluoride membrane, and probed with antibodies specifically rec-
ognizing phosphorylated Ser-839. E, serine 853 on mGluR1 is directly
phosphorylated by PKC upon mutation of Asp-854 to a permissive
amino acid. Wild-type (WT) GST-mGluR1-Cprox, GST-mGluR1-
Cprox (D854A), GST-mGluR1-Cprox (D854T), and mGluR1-Cprox
(S853A/D854A) were phosphorylated by purified PKC in vitro using
[-32P]ATP and then subjected to two-dimensional phosphopeptide
mapping, as described under “Experimental Procedures.” The figures
include representative phosphopeptide maps selected from 2–3 inde-
pendent experiments for each mutant.
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Cprox D854A and mGluR1-Cprox D854T revealed the appear-
ance of a new phosphopeptide (Fig. 2E). To confirm that the
new phosphopeptide was the result of the phosphorylation of
Ser-853, we made a double mutation, including both S853A and
D854A (GST-mGluR1-Cprox S853A/D854A). PKC phospho-
rylation of this fusion protein resulted in a peptide map lacking
the critical phosphopeptide and resembling the peptide map of
wild-type mGluR1 (Fig. 2E). These results strongly suggest
that the endogenous aspartic acid (Asp-854 of mGluR1) af-
fects the phosphorylation of the adjacent residue on mGluR1
(Ser-853), just as the adjacent threonine or aspartic acid affects
the phosphorylation of Ser-839 on mGluR5.
Our data, thus far, was entirely consistent with the direct
phosphorylation of Ser-839 on mGluR5 by PKC and an absence
of PKC phosphorylation of Thr-840. However, we wanted to
explore the possibility that certain isoforms of PKC might
preferentially phosphorylate Thr-840 or other nearby residues
in addition to Ser-839. All of our phosphorylation assays had
used a PKC mixture that consisted predominantly of , , and
 PKC. We therefore extended our analyses using a battery of
PKC isoforms to phosphorylate wild-type GST-mGluR5-Cprox
or GST-mGluR5-Cprox (S839A) (Fig. 3). We found that the
phosphopeptide maps derived from the phosphorylation assays
of different PKC isoforms were quite similar, indicating that
most of the PKC phosphorylation sites could be phosphorylated
by several different isoforms of PKC. Interestingly, many of the
PKC isoforms phosphorylated the peptide containing Ser-839
and Thr-840 (Fig. 3A), with PKC, PKC, and PKC being
most efficient. In contrast, PKC, -, and - did not appear to
phosphorylate Ser-839 at all. It should be noted that our ex-
periments only addressed the differential specificity of the PKC
isoforms in vitro and therefore do not necessarily reflect iso-
form specificity in vivo, where other factors, such as compart-
mentalization, may also play a critical role. However, impor-
tantly, the same peptide fragment was never phosphorylated
by any PKC isoform when Ser-839 was mutated to alanine (Fig.
3B). These data demonstrated that Ser-839 was the only resi-
due within the peptide that was phosphorylated by the variety
of PKC isoforms tested. Under no conditions was Thr-840, or
any other nearby residue, contained within that particular
tryptic peptide, phosphorylated by these same PKC isoforms.
These data further confirm the specificity of the PKC phospho-
rylation of serine 839.
If PKC phosphorylation of Ser-839 is critical for mGluR5-
elicited Ca2 oscillations, then the S839A mutation should
alter Ca2 transients elicited by mGluR5 activation. To in-
vestigate this, we expressed full-length mGluR5 wild type or
mutants in HeLa cells, and changes in intracellular Ca2
concentration in response to agonist application (500 M glu-
tamate, 250 s) were analyzed using a confocal microscope.
The intracellular Ca2 transients were classified as oscillat-
ing (representative response, Fig. 4A), or non-oscillating (see
“Experimental Procedures”) (8–10). Consistent with a critical
role for Ser-839 phosphorylation in the regulation of Ca2
signaling, the S839A mutation significantly prevented the
oscillating Ca2 response compared with mGluR5 wild type
FIG. 3. Several different PKC iso-
forms phosphorylate Ser-839 but not
Thr-840. GST-mGluR5-Cprox and GST-
mGluR5-Cprox (S839A) were phosphoryl-
ated in vitro by the recombinant PKC iso-
forms , I, II, , , , , , and 	 (25 ng
each) using the same reaction conditions
of 30 °C for 30 min. The phosphopeptide
containing Ser-839 and Thr-840 is indi-
cated with a white arrow. Phosphopeptide
mapping was performed as described un-
der “Experimental Procedures.”
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(Fig. 4B). Similar to previous studies (9, 10) and in agreement
with our phosphorylation data, activation of mGluR5 T840D
also resulted in a pronounced reduction of oscillating Ca2
responses (Fig. 4B). However, consistent with our finding
that it is Ser-839 and not Thr-840 phosphorylation that is
important for regulating Ca2 signaling, T840A (which is
permissive for Ser-839 phosphorylation) exhibited Ca2 os-
cillations that were indistinguishable from mGluR5 wild-
type Ca2 responses (Fig. 4B). Thus phosphorylation of Ser-
839 is the critical molecular determinant for the Ca2
oscillations induced by mGluR5 activation.
Previous studies (8, 10) have characterized the mGluR5-
elicited Ca2 oscillations pharmacologically. For example, us-
ing several PKC inhibitors, Kawabata et al. (9, 10) determined
that the oscillations were dependent on PKC but not on other
kinases, such as cAMP-dependent protein kinase, protein ki-
nase G, or calcium/calmodulin-dependent protein kinase II.
Therefore, we also investigated the PKC dependence of
mGluR5-elicited Ca2 oscillations, specifically comparing wild-
type mGluR5 to mGluR5 T840A. Cells expressing mGluR5
T840A were treated with PMA for 12 h to down-regulate PKC
activity (8). Under these conditions, both mGluR5 wild-type
and mGluR5 T840A no longer consistently produced Ca2 os-
cillations (Fig. 5), further confirming that PKC phosphoryla-
tion of Thr-840 is not the essential PKC event regulating
Ca2 oscillations.
DISCUSSION
Many studies have implicated PKC as an important regula-
tor of mGluR5 function (10, 14–16). One of the most convincing
examples of PKC regulating mGluR signaling is that of
mGluR5-mediated Ca2 oscillations. The activation of the
Group 1 metabotropic glutamate receptors, mGluR1 and
mGluR5, results in intracellular Ca2 release, but mGluR5
activation is unique in that it triggers Ca2 oscillations. It is
known that the proximal region of the mGluR5 C terminus is
the critical determinant regulating the Ca2 oscillations, and
until now, it has been widely accepted that PKC phosphoryla-
tion of Thr-840 within that region of mGluR5 was the essential
FIG. 4. PKC phosphorylation of Ser-839 on mGluR5 regulates
Ca2 responses evoked by activation of mGluR5. HeLa cells were
transfected with mGluR5 wild type (WT), mGluR5 S839A, mGluR5
T840A, or mGluR5 T840D full-length expression constructs. Calcium
responses were monitored under confocal microscope for 250 s in time
scan mode after treatment of glutamate (500 M). Calcium responses
were classified as oscillating or non-oscillating, as described under
“Experimental Procedures.” A, representative trace of oscillating Ca2
response to agonist application in cell expressing wild-type mGluR5. B,
the number of cells that displayed the calcium oscillations was counted
and depicted as a percentage of the total number of cells that showed
any calcium response. The percentages of responding cells that oscil-
lated were 51.1  6.4, 45.9  6.4, 22.9  3.4, and 18.3  2.5% for
mGluR5 wild-type, mGluR5 T840A, mGluR5 S839A, and mGluR5
T840D, respectively. *, p  0.01 versus wild-type control. All results are
expressed as means  S.E. for four independent experiments. Total
numbers of cells counted over four independent experiments were 234,
197, 219, and 221 for mGluR5 S839A, mGluR5 T840D, mGluR5 T840A,
and mGluR5 wild-type, respectively. Analysis of variance was used to
assess the difference between multiple groups.
FIG. 5. Mutation of threonine 840 does not eliminate the PKC
regulation of mGluR5-elicited Ca2 oscillations. HeLa cells trans-
fected with mGluR5 wild-type (WT) or mGluR5 T840A full-length ex-
pression constructs were treated with phorbol 12-myristate 13-acetate
(PMA) for 12 h to down-regulate PKC. Calcium responses to glutamate
were assessed as described in the legend to Fig. 4. The percentages of
responding cells that oscillated were 47.9  5.4% for PMA wild-type
versus 16.9  5.3% for PMA wild-type, and 44.4  4.7% for PMA
T840A versus 18.7  4.2% for PMA T840A. *, p  0.01 versus PMA
control. All results are expressed as means  S.E. for three independ-
ent experiments. Total numbers of cells counted over three independent
experiments were 119, 108, 102, and 98 for mGluR5 T840A (PMA),
mGluR5 T840A (PMA), mGluR5 wild-type (PMA), and mGluR5
wild-type (PMA), respectively. Student’s t test was used to assess the
difference between PMA (black bar) and PMA (shaded bar).
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mechanism (8–10, 19–22). This is based on mutagenesis data
in which altering Thr-840 to aspartic acid perturbs mGluR5
Ca2 oscillations. We have used biochemical phosphorylation
assays to specifically characterize the PKC phosphorylation of
the portion of the mGluR5 C terminus surrounding Thr-840.
Strikingly, we found that Thr-840 is not a PKC substrate, and
its phosphorylation does not play any role in the PKC regula-
tion of mGluR5-elicited Ca2 oscillations. Instead, an adjacent
residue, Ser-839, is directly phosphorylated by PKC, and phos-
phorylation of this residue regulates mGluR5-dependent
Ca2 oscillations.
Although Thr-840 is not directly phosphorylated, both our
study and that of Kawabata et al. (10) show that a threonine
residue at the 840 position, not an aspartic acid, is essential for
mGluR5-elicited Ca2 oscillations. We then demonstrated that
this could be attributed to a permissive or structural role for
Thr-840 in allowing the phosphorylation of Ser-839 on
mGluR5. Although the original study by Kawabata et al. used
peptide map analysis to analyze the phosphorylation of the
critical region of mGluR5, they never evaluated the T840A
mutation. This experiment would have revealed that Thr-840
was not the residue directly phosphorylated by PKC.
We also showed that the analogous residue Asp-854 in
mGluR1 inhibits the PKC phosphorylation of the conserved
serine in mGluR1, Ser-853. When mGluR1 Asp-854 is mu-
tated to a permissive residue, D854A, we observed PKC phos-
phorylation of Ser-853. These findings are entirely consistent
with the original findings in which activation of mGluR5 con-
taining the T840D mutation resulted in mGluR1-like intra-
cellular calcium release, and activation of mGluR1 containing
the D854T mutation resulted in mGluR5-like Ca2 oscillations.
Although our experiments are the first to demonstrate that
Thr-840 is not directly phosphorylated by PKC, other studies
suggest that Thr-840 may not be a substrate for PKC. For
example, the T840A and T840D mutations in mGluR5 have
been reported to differentially regulate PKC oscillation pat-
terns upon mGluR5 activation (7, 21). These results cannot
be explained by the direct phosphorylation of Thr-840 on
mGluR5 by PKC (or lack of phosphorylation of serine 854 of
mGluR1), because both of these mutations would abolish
phosphorylation of this particular residue and would be pre-
dicted to have similar phenotypes. However, in neither study
was an alternative mechanism for PKC regulation of mGluR5
signaling identified. Our findings that PKC directly phospho-
rylates Ser-839 and that Thr-840 is permissive for Ser-839
phosphorylation are consistent with these reports and recon-
cile much of the data found in the literature. Taken together,
these data are consistent with a role for PKC phosphorylation
of Ser-839 specifically regulating mGluR5-elicited Ca2 (and
perhaps PKC and IP3) oscillations.
We used an in vitro phosphorylation assay followed by phos-
phopeptide map analyses to determine that Ser-839 is phos-
phorylated by PKC but that Thr-840 is not. Initially we used a
PKC mixture that consisted predominantly of , , and  iso-
forms in all of our phosphorylation assays. However, we
wanted to explore the possibility that particular PKC isoforms
might preferentially phosphorylate Ser-839 or Thr-840. A re-
cent study reported that PKC specifically phosphorylates Thr-
840, although no biochemical assays of phosphorylation were
conducted (21). To address the possibility that specific isoforms
might preferentially phosphorylate Thr-840, we used a battery
of PKC isoforms to phosphorylate wild-type GST-mGluR5-
Cprox or GST-mGluR5-Cprox (S839A) (Fig. 3). We found that
Thr-840 was not phosphorylated by any of the PKC isoforms
used in our assay, including PKC. Once again these data
supported a purely permissive or structural role for Thr-840 in
allowing Ser-839 to be a substrate for PKC phosphorylation.
Finally, to explore whether the mGluR5 T840A Ca2 oscilla-
tions were PKC-dependent, we treated cells expressing
mGluR5 T840A with PMA for a prolonged period of time to
down-regulate PKC. We found that PKC down-regulation in-
hibited the oscillations. Thus, mGluR5 T840A-elicited Ca2
oscillations were indeed PKC-dependent, consistent with PKC
directly phosphorylating Ser-839 and not Thr-840.
Our results clearly demonstrated a central role for the PKC
phosphorylation of Ser-839 in regulating mGluR5 Ca2 oscil-
lations in heterologous cells. Furthermore, our studies revealed
a unique substrate-specific phosphorylation event that differ-
entiates the regulation of the Group 1 mGluR-mediated intra-
cellular Ca2 release. Such a precisely regulated difference in
intracellular signaling between mGluR5 and mGluR1 is ex-
tremely provocative, and our studies defining the precise PKC
substrate within mGluR5 that is phosphorylated will facilitate
more rigorous studies. However, it is also clear that the regu-
lation of mGluR5-elicited Ca2 oscillations must be more com-
plicated than the PKC phosphorylation of a single residue. The
fact that all responding cells do not oscillate (Fig. 4) lends
support to the notion that other factors are at play. This is also
apparent by the many complexities in the Group 1 mGluR Ca2
signaling literature (8, 23–25).
The role of Ca2 oscillations in neurons is not understood,
although it is clear that the frequency, duration, and spatial
location of calcium signals are critical for the precise regulation
of signal transduction and gene expression in other cellular
systems (26–28). A recent study reported that mutating Asp-
854 on mGluR1 to threonine (to mimic mGluR5) does not yield
oscillations in Purkinje neurons (22), making it unclear how
Ca2 oscillations in glia and heterologous cells relate to Ca2
transients in neurons. These recent findings suggest that, at
least in Purkinje neurons, the regulation of Ca2 transients
may be more complex than previously believed and illustrate
the importance of evaluating mGluR signaling in neurons. By
precisely characterizing the molecular determinants underly-
ing PKC phosphorylation of mGluR5, our study will facilitate
more vigorous and accurate analyses of mGluR-regulated
Ca2, PKC, and IP3 oscillations in vivo.
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